(UroToday.com) The 2024 IBCN annual meeting included a session on molecular subtyping in the 2024, featuring a presentation by Dr. Saum Ghodoussipour discussing the LUMBER-NAC trial in progress. A ...
Giredestrant has a stronger anti-proliferative effect than anastrozole in patients with estrogen receptor-positive, HER2-negative, previously untreated early breast cancer, a new study suggests.
Researchers investigated the efficacy of total neoadjuvant treatment followed by nonoperative management in patients with locally advanced rectal cancer.
Department of Oncology and Radiotherapy, Medical University of Gdańsk, 80-211 Gdańsk, Poland In The Lancet Respiratory Medicine, Ze-Rui Zhao and colleagues provide us with early results of SACTION01, ...